The pharmaceutical blockbuster model is wobbling. And no single franchise is safe. While king Keytruda, Merck’s stalwart oncology drug, continues to rule the first half of 2025 with $15.2B in sales (Q1 $7.2B, Q2 $8.0B), its U.S. patent expiry in 2028 the single biggest loss of exclusivity event on the horizon. In the U.S., Medicare…
Big Pharma shakeup: This chart reveals the new top dog of 2023
In the Aesopian fable, the tortoise’s steady focus and persistence overcomes the hare’s bursts of speed. 2023 saw a similar shift in the pharma sector. While Pfizer, thanks to blockbuster COVID vaccine sales, rocketed to unprecedented heights in 2022 surpassing $100 billion in revenue, its fortunes reversed in 2023. As COVID product demand plummeted, Pfizer’s…